Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SERVAL: Seasonal R21 Mass Vaccination for Malaria
NCT06578572Phase 3Recruiting
- Sponsor
- London School of Hygiene & Tropical Medicine
- Start
- May 2024
- Primary completion
- Dec 2024
- Modality
- Recombinant Protein Vaccines
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of R21/Matrix-M in malaria (2 arms), sponsored by London School of Hygiene & Tropical Medicine. Primary endpoint: Prevalence of malaria infection by PCR. Started May 2024; status: recruiting.
02
Drugs
R21/Matrix-M
03
Conditions
malaria
Beyond the preview
Go deeper on NCT06578572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06578572.